Hantz Financial Services Inc. Has $12.30 Million Position in Penumbra, Inc. (NYSE:PEN)

Hantz Financial Services Inc. trimmed its position in Penumbra, Inc. (NYSE:PEN) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,792 shares of the company’s stock after selling 1,244 shares during the period. Hantz Financial Services Inc. owned approximately 0.13% of Penumbra worth $12,300,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of PEN. State Street Corp raised its holdings in Penumbra by 0.3% in the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock worth $240,298,000 after purchasing an additional 3,863 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Penumbra by 3,832.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock valued at $71,564,000 after purchasing an additional 358,932 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in shares of Penumbra in the third quarter valued at approximately $1,092,000. AlphaCentric Advisors LLC acquired a new stake in shares of Penumbra during the third quarter worth $777,000. Finally, LMR Partners LLP acquired a new stake in shares of Penumbra during the third quarter worth $2,330,000. Institutional investors own 88.88% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $237.28, for a total transaction of $3,559,200.00. Following the sale, the chief executive officer now directly owns 852,582 shares of the company’s stock, valued at approximately $202,300,656.96. This represents a 1.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Lambert Shiu sold 1,798 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $242.56, for a total transaction of $436,122.88. Following the completion of the transaction, the chief accounting officer now directly owns 20,682 shares in the company, valued at approximately $5,016,625.92. This represents a 8.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,819 shares of company stock worth $8,129,483 in the last quarter. Corporate insiders own 5.00% of the company’s stock.

Penumbra Stock Down 0.9 %

Shares of PEN opened at $270.40 on Wednesday. The firm has a market cap of $10.38 billion, a P/E ratio of 314.42, a price-to-earnings-growth ratio of 2.02 and a beta of 0.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 5.82. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $277.89. The firm’s 50-day simple moving average is $249.26 and its 200 day simple moving average is $217.39.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.16. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. The firm had revenue of $301.04 million for the quarter, compared to analysts’ expectations of $297.36 million. During the same quarter last year, the business earned $0.67 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, analysts forecast that Penumbra, Inc. will post 2.81 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on PEN. Oppenheimer assumed coverage on Penumbra in a report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price for the company. Canaccord Genuity Group boosted their price objective on shares of Penumbra from $260.00 to $323.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Truist Financial boosted their price target on shares of Penumbra from $240.00 to $285.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Royal Bank of Canada raised their price target on Penumbra from $205.00 to $222.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Penumbra has a consensus rating of “Moderate Buy” and an average target price of $261.36.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.